Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D.
暂无分享,去创建一个
[1] D. Trump,et al. The role of vitamin D in cancer prevention and treatment. , 2012, Rheumatic diseases clinics of North America.
[2] M. Grossbard,et al. Vitamin D and breast cancer. , 2012, The oncologist.
[3] C. Davis,et al. Vitamin D and colon cancer , 2011, Expert review of gastroenterology & hepatology.
[4] D. Feldman,et al. Anti-inflammatory Activity of Calcitriol in Cancer , 2011 .
[5] C. Mathieu,et al. Vitamin D: a pleiotropic hormone. , 2010, Kidney international.
[6] M. Holick. Vitamin D: Physiology, Molecular Biology, and Clinical Applications , 2010 .
[7] L. Raisz,et al. Prostaglandins in bone: bad cop, good cop? , 2010, Trends in Endocrinology & Metabolism.
[8] K. Knudsen,et al. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer , 2010, Trends in Endocrinology & Metabolism.
[9] N. Weigel,et al. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. , 2010, Endocrinology.
[10] D. Feldman,et al. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. , 2010, Endocrine-related cancer.
[11] K. Knudsen,et al. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. , 2010, Endocrinology.
[12] J. Adams,et al. Update in vitamin D. , 2010, The Journal of clinical endocrinology and metabolism.
[13] G. Dranitsaris,et al. A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases , 2010, Cancer.
[14] D. Trump,et al. Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy , 2010, Cancer journal.
[15] D. Feldman,et al. Anti-inflammatory Activity of Calcitriol That Contributes to Its Therapeutic and Chemopreventive Effects in Prostate Cancer , 2010 .
[16] S. Srinivas,et al. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. , 2009, Anticancer research.
[17] D. Feldman,et al. Unraveling insulin-like growth factor binding protein-3 actions in human disease. , 2009, Endocrine reviews.
[18] Sam S. Chang,et al. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. , 2009, The Journal of urology.
[19] N. Weigel,et al. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. , 2009, Endocrinology.
[20] H. Bischoff-Ferrari. Vitamin D in Fracture Prevention and Muscle Function and Fall Prevention , 2009 .
[21] S. Gümüşlü,et al. Cyclooxygenase-2 in Cancer and Angiogenesis , 2009, Angiology.
[22] Bryan M. Gillard,et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. , 2009, Cancer research.
[23] S. Srinivas,et al. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer , 2009, Dermato-endocrinology.
[24] Jining Wang,et al. Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy. , 2009, Endocrine reviews.
[25] F. Fulfaro,et al. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C , 2009, Medical oncology.
[26] D. Bikle. Nonclassic actions of vitamin D. , 2009, The Journal of clinical endocrinology and metabolism.
[27] J. Pinski,et al. A phase II study of high‐dose calcitriol combined with mitoxantrone and prednisone for androgen‐independent prostate cancer , 2008, BJU international.
[28] E. Giovannucci,et al. Vitamin D and Prevention of Colorectal Adenoma: A Meta-analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.
[29] A. Muñoz,et al. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. , 2008, Anticancer research.
[30] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[31] J. Meyerhardt,et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Nilanjan Chatterjee,et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. , 2008, Journal of the National Cancer Institute.
[33] Masao Omata,et al. Inflammation and cancer: Role of nuclear factor‐kappaB activation , 2008, Cancer science.
[34] D. McNeel,et al. Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.
[35] E. Rankin,et al. The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.
[36] N. Kyprianou,et al. Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance , 2008, Journal of cellular biochemistry.
[37] P. Allavena,et al. Pathways connecting inflammation and cancer. , 2008, Current opinion in genetics & development.
[38] W. Fawzi,et al. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial , 2007, International journal of cancer.
[39] R. Mehta,et al. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture , 2008, Breast Cancer Research and Treatment.
[40] E. Balint,et al. CHAPTER 13 – Vitamin D: Biology, Action, and Clinical Implications , 2008 .
[41] Long Wang,et al. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. , 2008, Medical hypotheses.
[42] E. Giovannucci. Vitamin D status and cancer incidence and mortality. , 2008, Advances in experimental medicine and biology.
[43] S. Ingles,et al. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. , 2007, American journal of epidemiology.
[44] J. Welsh. Targets of Vitamin D Receptor Signaling in the Mammary Gland , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] D. Peehl,et al. Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti‐Inflammatory Activity , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[46] G. Francini,et al. Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel , 2007, BJU international.
[47] Z. Tulassay,et al. Carcinogenesis in Inflammatory Bowel Disease , 2007, Digestive Diseases.
[48] D. Trump. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators , 2007 .
[49] D. Trump,et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.
[50] N. Weigel. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. , 2007, Nutrition reviews.
[51] J. Welsh,et al. Calcium, vitamin D and the vitamin D receptor: impact on prostate and breast cancer in preclinical models. , 2007, Nutrition reviews.
[52] Louise R Howe,et al. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.
[53] M. Schwab,et al. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. , 2007, Molecular immunology.
[54] D. S. St. Clair,et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1α,25-dihydroxyvitamin D3 in prostate cancer cells , 2007, Molecular Cancer Therapeutics.
[55] S. Markowitz. Aspirin and colon cancer--targeting prevention? , 2007, The New England journal of medicine.
[56] L. Mosekilde,et al. [Vitamin D and breast cancer]. , 2007, Ugeskrift for laeger.
[57] D. Dang,et al. 1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells , 2007, Molecular Cancer Therapeutics.
[58] Jianfeng Xu,et al. Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.
[59] E. Giovannucci,et al. Vitamin D and prevention of breast cancer: Pooled analysis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[60] A. Bonanomi,et al. The Vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn's disease , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[61] G. Schwartz,et al. Vitamin D status and cancer: new insights , 2007, Current opinion in clinical nutrition and metabolic care.
[62] D. Dang,et al. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. , 2007, Molecular cancer therapeutics.
[63] S. Rose-John,et al. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[64] C. Mathieu,et al. Vitamin D and cancer , 2013, Cell cycle.
[65] Melissa L. Johnson,et al. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. , 2006, Seminars in oncology.
[66] A. Whittemore,et al. Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States) , 2006, Cancer Causes & Control.
[67] C. Ryan,et al. High dose calcitriol may reduce thrombosis in cancer patients , 2006, British journal of haematology.
[68] R. DiPaola,et al. Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice , 2006, Clinical Cancer Research.
[69] Jorge Yao,et al. 1 a , 25-dihydroxyvitamin D 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis , 2006 .
[70] Brian L. Cohen,et al. Cyclooxygenase‐2 (cox‐2) expression is an independent predictor of prostate cancer recurrence , 2006, International journal of cancer.
[71] T. P. Pretlow,et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis , 2006, Proceedings of the National Academy of Sciences.
[72] Jun Sun,et al. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor , 2006 .
[73] B. Karlan,et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. , 2006, Cancer research.
[74] E. Crawford,et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone‐refractory prostate cancer , 2006, Cancer.
[75] A. Muñoz,et al. Effects of 1α,25-Dihydroxyvitamin D3 in Human Colon Cancer Cells , 2006 .
[76] H. Koeffler,et al. Vitamin D compounds: activity against microbes and cancer. , 2006, Anticancer research.
[77] F. Sinicrope. Targeting cyclooxygenase‐2 for prevention and therapy of colorectal cancer , 2006, Molecular carcinogenesis.
[78] D. Trump,et al. Phase II trial of high‐dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‐independent prostate cancer , 2006, Cancer.
[79] L. Davis,et al. RNA interference–mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor , 2006, Molecular Cancer Therapeutics.
[80] D. Peehl,et al. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. , 2006, Cancer research.
[81] Glenville Jones,et al. Promise of vitamin D analogues in the treatment of hyperproliferative conditions , 2006, Molecular Cancer Therapeutics.
[82] John Robbins,et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. , 2006, The New England journal of medicine.
[83] Martin Lipkin,et al. The role of vitamin D in cancer prevention. , 2006, American journal of public health.
[84] F. Sellke,et al. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. , 2006, Cardiovascular research.
[85] C. Garland,et al. Do sunlight and vitamin D reduce the likelihood of colon cancer? , 1980, International journal of epidemiology.
[86] A. Muñoz,et al. Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. , 2006, Anticancer research.
[87] A. Douvdevani,et al. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[88] Xianquan Zhan,et al. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. , 2005, Cancer research.
[89] A. Llombart‐Bosch,et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. , 2005, European urology.
[90] Laurent Lessard,et al. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study , 2005, British Journal of Cancer.
[91] H. Koeffler,et al. Vitamin D compounds in leukemia , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[92] D. Peehl,et al. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity , 2005, Molecular and Cellular Endocrinology.
[93] David Feldman,et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. , 2005, Cancer research.
[94] N. Weigel,et al. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells , 2005, The Prostate.
[95] S. Nagpal,et al. Noncalcemic actions of vitamin D receptor ligands. , 2005, Endocrine reviews.
[96] Marin L. Gantner,et al. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. , 2005, Biochemical and biophysical research communications.
[97] Georg Bartsch,et al. Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.
[98] C. Shapiro,et al. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. , 2005, The Journal of clinical endocrinology and metabolism.
[99] A. Bergh,et al. Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer , 2005, Clinical Cancer Research.
[100] P. Lønning,et al. Aromatase Inhibition: Translation into a Successful Therapeutic Approach , 2005, Clinical Cancer Research.
[101] A. Muñoz,et al. SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications , 2005, British Journal of Cancer.
[102] R. Vieth,et al. Pilot Study: Potential Role of Vitamin D (Cholecalciferol) in Patients With PSA Relapse After Definitive Therapy , 2005, Nutrition and cancer.
[103] M. Hewison. CHAPTER 79 – Extra-renal 1α-Hydroxylase Activity and Human Disease , 2005 .
[104] K. Colston. CHAPTER 93 – Vitamin D and Breast Cancer , 2005 .
[105] H. Cross. CHAPTER 95 – Vitamin D and Colon Cancer , 2005 .
[106] J. O'kelly. CHAPTER 96 – Vitamin D and Hematological Malignancy , 2005 .
[107] A. Krishnan. CHAPTER 94 – Vitamin D and Prostate Cancer , 2005 .
[108] Edward Giovannucci,et al. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States) , 2005, Cancer Causes & Control.
[109] J. Lutterbaugh,et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[110] J. Welsh. Vitamin D and breast cancer: insights from animal models. , 2004, The American journal of clinical nutrition.
[111] V. Go,et al. Vitamin D and colon carcinogenesis. , 2004, The Journal of nutrition.
[112] W. Isaacs,et al. Cyclooxygenases in cancer: progress and perspective. , 2004, Cancer letters.
[113] J. Brooks,et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[114] A. Bergh,et al. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase‐2, Bcl‐2, and cell proliferation in the glandular epithelium , 2004, The Prostate.
[115] S. Itzkowitz,et al. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[116] P. Malloy,et al. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. , 2004, Molecular endocrinology.
[117] J. Lewin,et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.
[118] T. Beer,et al. Calcitriol in cancer treatment: from the lab to the clinic. , 2004, Molecular cancer therapeutics.
[119] L. Lessard,et al. Expression of NF‐κB in prostate cancer lymph node metastases , 2004 .
[120] M. Lucia,et al. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. , 2004, The Journal of urology.
[121] N. Bundred,et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ , 2004, British Journal of Cancer.
[122] A. Rabson,et al. NF‐κB activation in human prostate cancer: Important mediator or epiphenomenon? , 2004 .
[123] F. Sinicrope,et al. Role of cyclooxygenase-2 in colorectal cancer , 2004, Cancer and Metastasis Reviews.
[124] E. Yang,et al. Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm* , 2003, Journal of Biological Chemistry.
[125] A. Giaccia,et al. HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.
[126] T. Yanase,et al. Aromatase in bone: roles of Vitamin D3 and androgens , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[127] G. Luo,et al. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation , 2003, Oncogene.
[128] Yuan‐Chang Chung,et al. Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.
[129] Kyucheol Cho,et al. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways , 2003, Oncogene.
[130] Kelly Smith,et al. Vitamin D-3 receptor as a target for breast cancer prevention. , 2003, The Journal of nutrition.
[131] W. Weichert,et al. Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma , 2003, Cancer.
[132] G. Semenza,et al. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.
[133] H. Mukhtar,et al. Cyclooxygenase-2 and prostate carcinogenesis. , 2003, Cancer letters.
[134] T. Beer,et al. High‐dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma , 2003, Cancer.
[135] M. Holick,et al. Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase and its implication in prostate cancer , 2003, Journal of cellular biochemistry.
[136] T. Stamey,et al. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[137] L. Coussens,et al. Inflammation and cancer , 2002, Nature.
[138] J. Welsh,et al. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[139] D. Peehl,et al. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. , 2002, The Journal of urology.
[140] G. Åkerström,et al. 25-hydroxyvitamin D3-1α-hydroxylase expression in normal and pathological parathyroid glands , 2002 .
[141] L. Norton,et al. Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.
[142] Andrew Dannenberg,et al. COX-2 in cancer--a player that's defining the rules. , 2002, Journal of the National Cancer Institute.
[143] P. Adegboyega,et al. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. , 2002, American journal of physiology. Cell physiology.
[144] Michael Karin,et al. NF-κB at the crossroads of life and death , 2002, Nature Immunology.
[145] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[146] D. Heber,et al. 1α, 25-(OH)2-D3 and its synthetic analogue decrease tumor load in the Apcmin mouse , 2002 .
[147] J. Isola,et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.
[148] W. Boon,et al. Aromatase--a brief overview. , 2002, Annual review of physiology.
[149] Edgar M Moran,et al. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[150] W. Isaacs,et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. , 2001, Cancer Research.
[151] M. A. Blankenstein,et al. Aromatase and COX-2 expression in human breast cancers , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[152] S. Catz,et al. Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer , 2001, Oncogene.
[153] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[154] J. Masferrer,et al. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. , 2001, Scandinavian journal of gastroenterology.
[155] J. Bartek,et al. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. , 2001, Molecular endocrinology.
[156] H. Cross,et al. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. , 2001, Biochemical and biophysical research communications.
[157] P. Cohen,et al. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. , 2001, The Journal of urology.
[158] H. Müller,et al. Germline alterations in the cyclooxygenase‐2 gene are not associated with the development of extracolonic manifestations in a large Swiss familial adenomatous polyposis kindred , 2000, International journal of cancer.
[159] N. Bundred,et al. 1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .
[160] D. Feldman,et al. 1α,25-Dihydroxyvitamin D3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells , 2000 .
[161] T. Hla,et al. Expression of cyclooxygenase‐2 in prostate carcinoma , 2000, Cancer.
[162] L. G. García Rodríguez,et al. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. , 2000, Epidemiology.
[163] Y. Chen,et al. Prostaglandin E 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells , 2000, British Journal of Cancer.
[164] C. M. Hansen,et al. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. , 2000, Current pharmaceutical design.
[165] C. Paraskeva,et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. , 2000, Cancer research.
[166] A. Hoeflich,et al. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. , 2000, Cancer letters.
[167] C. Bonifer,et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. , 2000, The American journal of pathology.
[168] D. Bostwick,et al. Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.
[169] Randall Harris,et al. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. , 2000, Oncology reports.
[170] T. McDonnell,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2* , 1999 .
[171] M. Martin,et al. Regulation of estrogen receptor‐α gene expression by 1,25‐dihydroxyvitamin D in MCF‐7 cells , 1999 .
[172] C. N. Coleman,et al. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.
[173] D. Zhou,et al. Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. , 1999, Archives of biochemistry and biophysics.
[174] A. Kato,et al. High expression of cyclooxygenase‐2 in macrophages of human colonic adenoma , 1999, International journal of cancer.
[175] F. Robertson,et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. , 1999, Cancer letters.
[176] N. Weigel,et al. Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[177] D. Feldman,et al. Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity. , 1999, Endocrinology.
[178] D. Heitjan,et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. , 1999, Urology.
[179] D. Peehl,et al. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. , 1999, Endocrinology.
[180] Z. Kmietowicz. Patients with bone metastases need better care , 1998 .
[181] M. Uskoković,et al. Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[182] B. Wolff,et al. 1α,25‐Dihydroxyvitamin D3 decreases DNA binding of nuclear factor‐κB in human fibroblasts , 1998 .
[183] R. Coombes,et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. , 1998, British Journal of Cancer.
[184] T. Stamey,et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.
[185] T. Chen,et al. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[186] JoAnn E. Manson,et al. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.
[187] V. Laudone,et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. , 1998, Urology.
[188] D. Peehl,et al. 1α,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent. , 1997, Endocrinology.
[189] N. Weigel,et al. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.
[190] M. Hughes-Fulford,et al. Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. , 1997, Advances in experimental medicine and biology.
[191] C. Mendelson,et al. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. , 1996, Endocrinology.
[192] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[193] H. Tazaki,et al. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. , 1996, Biochemical and biophysical research communications.
[194] S Majewski,et al. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. , 1996, The journal of investigative dermatology. Symposium proceedings.
[195] L. Freedman,et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.
[196] S. Manolagas,et al. Erratum: Down-regulation of NF-κB protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3 (Proceedings of the National Academy of Sciences of the United States of America (November 21, 1995) 24 (524)) , 1996 .
[197] S. Manolagas,et al. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[198] G. Miller,et al. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[199] E. Corder,et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[200] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[201] L. Binderup,et al. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. , 1994, The Journal of endocrinology.
[202] D. Peehl,et al. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.
[203] G. Schwartz,et al. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.
[204] P. Reitsma,et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite , 1983, Nature.
[205] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.